Assessment of the extremity exposure during preparation and administration of 177 Lu – results of a multi-center study
Authors:
- Robert KollaardRKRobert Kollaard
- Łukasz AlbiniakŁAŁukasz Albiniak
- Nicolas CherbuinNCNicolas Cherbuin
- Jérémie DabinJDJérémie Dabin
- Hanan DatzHDHanan Datz
- Mahila FerrariMFMahila Ferrari
- Mikko HakulinenMHMikko Hakulinen
- Tereza KráčmerováTKTereza Kráčmerová
- Ann McCannAMAnn McCann
- Roel WiertsRWRoel Wierts
- Alessandra ZorzAZAlessandra Zorz
- 7 July 2026
- journal article
- Published by IOP Publishing in Journal of Radiological Protection
- Vol. 46 (3) , 031504
Abstract
Despite the increased use of 177 Lu in nuclear medicine (NM) over the last 10 years, the knowledge of the actual exposure of the extremities due to manipulation of this pharmaceutical is limited. The purpose of this study is to assess the extremity dose during the preparation and administration of 177 Lu-labelled radiopharmaceuticals in a wide range of NM practices. Workers in 10 NM centres throughout Europe wore a ring dosimeter on the base of the index finger of the non-dominant hand during preparation and/or administration of 177 Lu-labelled radiopharmaceuticals. Information on manipulated activity, tasks performed and protection measures was collected to allow sub-analyses. The median ring dose per monitoring interval was 0.16 mSv, with a maximum of 2.27 mSv in one month. The median normalised dose amounted 3.5 µ Sv GBq −1 (range 0.5–525). The highest monthly doses were found for workers involved in preparation of the pharmaceutical. The workers performing manual administrations (6.5 µ Sv GBq −1 ) showed higher normalised ring doses than those using the gravity method (3.5 µ Sv GBq −1 ) or a syringe pump (1.0 µ Sv GBq −1 ). Explanations for the wide range of normalised ring doses may be found in the different techniques applied in this study and the differences in minimum reportable doses of the dosimeters. When the data is extrapolated using a fingertip to ring dose ratio of 5, an annual fingertip dose of 1–136 mSv is found, with a median fingertip dose of 10 mSv per year. Extremity exposure during 177 Lu handling remained well below dose limits. The highest normalised doses occurred during preparation and manual administration. Overall, this investigation shows doses remain low when appropriate radiation protection measures (e.g. shielding and minimising time at short distance) are being applied.Keywords
Funding Information
- Pioneer Fund
This publication has 14 references indexed in Scilit:
- Development of the occupational exposure during the production and application of radiopharmaceuticals in GermanyJournal of Radiological Protection, 2024
- Finger doses due to 68Ga-labelled pharmaceuticals in PET departments—results of a multi-centre pilot studyJournal of Radiological Protection, 2023
- Evaluation of different types of lithium fluoride thermoluminescent detectors for ring dosimetry in nuclear medicineRadiation Measurements, 2022
- Review of extremity dosimetry in nuclear medicineJournal of Radiological Protection, 2021
- Need for harmonisation of extremity dose monitoring in nuclear medicine: results of a survey amongst national dose registries in EuropeJournal of Radiological Protection, 2021
- Nuclear medicine theranostics comes of ageThe Lancet Oncology, 2021
- Author Correction: Radiopharmaceutical therapy in cancer: clinical advances and challengesNature Reviews Drug Discovery, 2020
- Radiopharmaceutical therapy in cancer: clinical advances and challengesNature Reviews Drug Discovery, 2020
- Skin dose saving of the staff in 90Y/177Lu peptide receptor radionuclide therapy with the automatic dose dispenserNuclear Medicine Communications, 2016
- Evaluation of radiation safety in177Lu-PSMA therapy and development of outpatient treatment protocolJournal of Radiological Protection, 2016